Thermo Fisher Scientific (TMO)
NYSE Market Closed
Thermo Fisher Scientific is one of the world’s largest suppliers of tools, technologies, and services used in scientific research, healthcare diagnostics, biopharmaceutical production, and laboratory operations. The company sells analytical instruments, laboratory equipment, reagents, consumables, diagnostics products, and services to customers that include pharmaceutical and biotechnology companies, hospitals, clinical laboratories, universities, government agencies, and industrial labs.
The business is organized around several major operating areas. Its Life Sciences Solutions activities provide reagents, instruments, and workflows used in genetic analysis, cell biology, protein research, and bioproduction. Analytical Instruments offers technologies used to identify, measure, and characterize materials and biological samples, including mass spectrometry, chromatography, electron microscopy, and related systems. Specialty Diagnostics supplies clinical diagnostic tests and platforms across areas such as immunodiagnostics, microbiology, and transplant diagnostics. Laboratory Products and Biopharma Services includes everyday lab supplies, equipment, distribution, and contract research and manufacturing services for drug development customers.
Thermo Fisher’s scale is a key advantage. The company combines a broad product catalogue with global distribution, deep relationships with research and clinical customers, and a large installed base of instruments that drives recurring demand for consumables, service, and replacement products. Its brands include widely known names such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
TMO gives investors exposure to long-term spending on life sciences research, precision medicine, diagnostics, and pharmaceutical innovation. Its performance is influenced by research funding, biotech capital cycles, healthcare utilization, industrial demand, and customer investment in laboratory infrastructure.
Last updated
- Market Cap
- 176.13B
- P/E
- 25.72
- P/FCF
- 26.1
- P/S
- 3.9
- Enterprise Value
- 216.04B
- Sector
- —
- Industry
- Measuring and Controlling Devices, Not Elsewhere Classified
- Address
- 168 THIRD AVENUE, WALTHAM, MA, 02451
[Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Tissue Diagnostics Market to Reach USD 9.33 Bn by 2031 Driven by Expanding Precision Oncology Applications and Rising Adoption of Digital Pathology, Says Mordor Intelligence
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight
Cancer Biomarkers Market Outlook 2026–2031: Growing at a 8.65% CAGR, Driven by Precision Oncology and Early Detection Demand, Says Mordor Intelligence
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight
Global HPV Testing and Pap Test Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight
Global Personalized Medicine to Transform Modern Healthcare and Cross USD 1 Trillion by 2034 | DelveInsight
Global DNA Microarray Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2034 | DelveInsight
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Global Plasmid DNA Manufacturing Market Anticipates Impressive Growth Trajectory at a CAGR of ~18% by 2034 | DelveInsight
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) for Formulations Market Research Report 2026: Opportunities, Trends, Competitive Landscape, Strategies, Forecasts 2020-2035
Global Metagenomics Sequencing Market to Register Stunning Growth at a CAGR of ~13% by 2034 | DelveInsight
[Latest] Global Cell Culture Media Bags Market Size/Share Worth USD 2.28 Billion by 2035 at a 5.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Global AAV Vector Manufacturing Market Gearing Up for Outstanding Expansion at a CAGR of ~22% by 2034 | DelveInsight
Trends and Strategies in the 2026 Medical Device CMDO Market: Revenue to Exceed $354 Billion by 2033
Clinical Trial Data Visualization Research Report 2026: $1.82 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Omics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Barium Carbonate Market Projected to Reach USD 1326.74 Million by 2035, Amid Increasing Demand from Construction, Ceramics, and Electronics Industries | Report by SNS Insider
Allergy Diagnostic Market by Product & Service, Test Type, Allergen, End User - Global Forecast to 2031
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 176.13B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 216.04B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 25.72
- P/B
P/B ratio compares a company's share price to its book value per share.
- 3.39
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 3.9
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 19.61
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 4.78
- EPS
- 18.43
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.37%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 26.1
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 21.25
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 6.75B
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 13.19%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 6.05%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.83
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.53
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.15
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.22
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 2.6M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 473.95
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 11.01B | 12.22B | 11.12B | 10.86B | 10.36B |
| Gross profit | 4.43B | 5.01B | 4.58B | 4.41B | 4.24B |
| Operating income | 1.86B | 2.26B | 1.94B | 1.84B | 1.72B |
| EBITDA | 2.65B | 3.03B | 3.6B | 1.74B | 2.52B |
| Net income | 1.65B | 1.96B | 1.62B | 1.62B | 1.51B |
| Basic EPS | 4.44 | 5.22 | 4.28 | 4.28 | 3.99 |
| Diluted EPS | 4.43 | 5.21 | 4.27 | 4.28 | 3.98 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 113.28B | 110.34B | 103.02B | 101.23B | 99.04B |
| Total liabilities | 61.22B | 56.81B | 51.87B | 50.63B | 49.56B |
| Total equity | 51.94B | 53.41B | 51.03B | 50.48B | 49.36B |
| Cash & equivalents | 3.25B | 9.85B | 1.98B | 4.58B | 4.13B |
| Current assets | 22.32B | 28.71B | 22.3B | 24.58B | 23.38B |
| Current liabilities | 14.62B | 15.19B | 14.89B | 12.72B | 13.17B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 1.19B | 3.46B | 2.24B | 1.4B | 723M |
| Investing cash flow | -8.96B | 891M | -4.12B | -288M | -526M |
| Financing cash flow | 1.09B | 3.53B | -632M | -991M | -102M |
| Change in cash | -6.6B | 7.87B | -2.59B | 431M | 132M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | SD — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 144 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 8-K — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| form 4 | Form 4 — Chai Nelson | View Filing | |
| form 4 | Form 4 — CHANDY RUBY R | View Filing | |
| form 4 | Form 4 — HARRIS C MARTIN | View Filing | |
| form 4 | Form 4 — Jacks Tyler | View Filing | |
| form 4 | Form 4 — JOHNSON JENNIFER M | View Filing | |
| form 4 | Form 4 — Keith R. Alexandra | View Filing | |
| form 4 | Form 4 — Lynch Karen S | View Filing | |
| form 4 | Form 4 — Lynch Karen S | View Filing | |
| form 4 | Form 4 — Spar Debora L | View Filing | |
| form 4 | Form 4 — SPERLING SCOTT M | View Filing | |
| form 4 | Form 4 — WEISLER DION J | View Filing | |
| form 4 | Form 4 — WEISLER DION J | View Filing | |
| edgar index | DEFA14A — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 10-Q — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 144 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| form 4 | Form 4 — Pettiti Gianluca | View Filing | |
| edgar index | 8-K — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEFA14A — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | ARS — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | DEF 14A — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | SCHEDULE 13G/A — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 8-K — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 144 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| form 4 | Form 4 — Shafer Michael D | View Filing | |
| edgar index | 3 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| form 3 | Form 3 — Meyer James | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 4 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| edgar index | 144 — THERMO FISHER SCIENTIFIC INC. | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing | |
| form 4 | Form 4 — CASPER MARC N | View Filing |